Form 4: RA Capital Management Reports Beneficial Ownership Changes in Artiva Biotherapeutics Following IPO

RA Capital Management and related entities report changes in beneficial ownership of Artiva Biotherapeutics common stock following the company's initial public offering.

Summary

• RA Capital Management, L.P., along with related funds and individuals, filed a Form 4 detailing changes in beneficial ownership of Artiva Biotherapeutics, Inc. (ARTV) common stock on July 22, 2024.
• The filing reflects the conversion of preferred stock and simple agreements for future equity (SAFE) into common stock upon the closing of Artiva Biotherapeutics' IPO.
• RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus III Fund, L.P., and a separately managed account hold significant amounts of Artiva Biotherapeutics common stock.
• Peter Kolchinsky and Rajeev Shah, managing members of RA Capital Management GP, LLC, disclaim beneficial ownership except to the extent of their pecuniary interest.
• The reported transactions include the conversion of Series A and Series B Preferred Stock into common stock on a one-for-one basis.
• Additionally, outstanding SAFEs totaling $3,296,448.20 and $1,412,763.51 were converted into common stock at a 15% discount to the IPO price.
• Following these transactions, RA Capital and related entities hold a substantial amount of Artiva Biotherapeutics common stock.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing, indicating a neutral to slightly positive sentiment due to the completion of the IPO and conversion of securities.

Positives

• The conversion of preferred stock and SAFEs into common stock simplifies Artiva Biotherapeutics' capital structure following the IPO.
• RA Capital's continued significant holdings demonstrate ongoing investment in Artiva Biotherapeutics.

Industry Context

Form 4 filings are standard practice following significant transactions like IPOs, providing transparency into ownership changes and insider activity.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for reporting changes in beneficial ownership, ensuring transparency in the market.
• The conversion of preferred stock and SAFEs into common stock upon an IPO is a common practice to simplify the capital structure of newly public companies.
• RA Capital's investment size is significant, but not unusual for a major investor in a biotech company going public.

Stakeholder Impact

• Shareholders: Provides transparency regarding ownership changes post-IPO.
• Employees: No direct impact, but successful IPO can boost morale.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates